medicines
-
20-Jun-2018 IP Watch
The myth behind health and trade agreements – Q&A with Othoman Mellouk
Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade.
-
19-Jun-2018 Sydney Morning Herald
Tough talk over medicine and cheese as Australia and Europe seek a $37b trade deal
Trade Minister Steven Ciobo has promised to take a hard line with Europe on the question of cheap medicines and his counterpart Cecilia Malmström foresees “difficult” negotiations over Australian producers using European names such as "parmesan".
-
22-May-2018 La Diaria
Impactos del TLC Mercosur-UE en la salud
Amenaza acceso a medicamentos y etiquetado de alimentos, según organizaciones europeas.
-
21-May-2018 La Diaria
Industrias Farmacéuticas latinoamericanas expresaron discrepancia con TLC entre Mercosur y la UE
La asociación instó a los gobiernos del Mercosur a que “no acepten nuevos y más altos estándares de protección y observancia de propiedad intelectual que vulneren las flexibilidades contempladas en el Acuerdo sobre los Aspectos de los Derechos de Propiedad Intelectual, y que limitan el acceso a los medicamentos”.
-
14-May-2018 Scoop World
Reject Trump’s threat to affordable medicines through TPP
Government should reject Trump’s threat to affordable medicines through TPP and other trade deals.
-
2-May-2018 IP Watch
Ukraine eyes patent law reform after civil society push on medicines access
Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups for better access to affordable medicines and healthcare.
-
27-Apr-2018 La Presse
Médicaments et libre-échange avec l’Europe: une décision pourrait coûter 270 millions
La prolongation de la durée des brevets des médicaments dans le cadre de l’entente de libre-échange entre le Canada et l’Union européenne pourrait coûter jusqu’à 270 millions au gouvernement fédéral, selon un rapport.
-
27-Apr-2018 iPolitics
Drug patent extensions under CETA could cost feds $270M a year: PBO
Extended patent protections under Canada’s free trade deal with the European Union could cost the federal government some $270 million a year, according to a new report by the Parliamentary Budget Officer.
-
18-Apr-2018 IP Watch
Dozens of NGOs oppose proposed EU watch list on IP rights
A wide-ranging list of international nongovernmental organisations issued a letter to European Trade Commissioner Cecilia Malmström opposing a proposal to establish a “watch list” of countries deemed failing to protect European intellectual property.
-
12-Apr-2018 The Guardian
Costly medicines and pus in milk: a Brexit trade deal that’ll make you sick
The US trade barriers list shows that Liam Fox could let more than just chlorinated chicken into the UK. The public deserve to know the details
-
11-Apr-2018 MSF Access Campaign
MSF statement on resumption of EU-India FTA negotiations
Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft of the agreement, which has been under discussion since 2007, contains proposals from the EU that push for intellectual property (IP) provisions in the FTA that could jeopardize access to affordable medicines.
-
29-Mar-2018 Public Citizen
Renegociación del TLCAN: Amenazas a medicinas asequibles
El TLCAN de 1993 fue el primer acuerdo “comercial” que incluyó nuevos poderes de monopolio para las grandes compañías farmacéuticas.
-
29-Mar-2018 Public Citizen
Renegotiating NAFTA: Threats to affordable medicines
NAFTA was the first “trade” agreement that included new monopoly powers for Big Pharma companies.
-
22-Mar-2018 Quartz
America messed up the idea of free trade
US-led multilateral trade agreements have forced poorer foreign countries to honor patents in exchange for the benefits of bringing multi-national corporations—and their factory jobs—abroad.
-
12-Feb-2018 East Asia Forum
Tokyo’s drift towards intellectual property crusader
Japan’s role in RCEP negotiations appears to have been shaped by its participation in the TPP. Japan is now championing for expanded intellectual property right provisions which may block access to affordable medicines
-
6-Feb-2018 Toronto Star
NAFTA will undermine health unless Canada resists monopolies on medicines
Time and again, Canadians reaffirm their belief in the basic principle of equitable access to health care for all. But the spirit of this very Canadian principle remains in peril as NAFTA negotiations forge ahead.
-
5-Feb-2018 The Wire
Delhi’s RCEP talks on intellectual property shouldn’t forget India’s role as ‘Pharmacy of the World’
India must resist pressure from Japan and South Korea in RCEP for the elevated levels of intellectual property provisions and make sure the deal doesn’t limit the production of life-saving generic drugs in India and for many other developing countries of the world.
-
1-Feb-2018 Pharmacist
Over 100 organizations concerned with health sign open letter to Canadian, Mexican and US ministers of health and trade
AIDS, cancer, religious-based, teacher, and retiree advocacy groups were among the more than 100 organizations that recently signed a letter warning health and trade ministers of the United States, Canada, and Mexico not to undermine NAFTA’s access to affordable medicines.
-
30-Jan-2018 Parti Sosialis Malaysia
Towards a peoples charter on international trade agreements
It is now time we open up the dialogue on the kind of trade agreements that we want to see in place.
-
30-Jan-2018 Knowledge & News Network
India-Cambodia deliberates on financial support in agriculture, pharmaceuticals
India and Cambodia clinch a deal to work towards a Bilateral Investment Treaty which provides financial help to Southeast Asian nations.
